Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.

7609 Background: BATTLE is a phase II study to prospectively use biomarkers (BM) to guide treatment selection in patients (PTS) with advanced non-small cell lung cancer (NSCLC). This report details...